Welcome to our dedicated page for IVEDA SOLUTIONS SEC filings (Ticker: IVDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Iveda Solutions, Inc. (NASDAQ: IVDA, IVDAW) provide official details on the company’s corporate actions, securities, and Nasdaq listing status. These documents include current reports on Form 8-K and other required submissions that describe events such as warrant issuances, shareholder approvals and communications with The Nasdaq Stock Market LLC regarding continued listing requirements.
In one Form 8-K, Iveda reported that a majority of its outstanding shareholders approved the issuance of Series A and Series B common stock purchase warrants and the shares of common stock underlying those warrants, with the voting results presented in the filing. This type of disclosure helps investors understand how new warrants are authorized and the terms under which they may be exercised.
Another Form 8-K describes a letter from the Listing Qualifications Department of Nasdaq granting Iveda an extension to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1). The filing outlines the background of the non-compliance notice, the extension period and the potential consequences, including possible delisting and the availability of an appeal process under Nasdaq rules.
Earlier company communications also discuss a private placement of common stock and warrants pursuant to a securities purchase agreement with institutional investors, including the planned filing of registration statements covering the resale of the shares of common stock and shares issuable upon exercise of the warrants. Related registration rights and offering details are typically addressed in filings with the Securities and Exchange Commission.
On this SEC filings page, users can access Iveda’s public filings as they appear on the SEC’s EDGAR system, including annual and quarterly reports when filed, current reports on Form 8-K, and documents related to warrant issuances and capital raises. AI-powered tools can assist by summarizing key points, such as the nature of material events, the structure of warrant and equity offerings, and updates on listing compliance, helping readers interpret the regulatory disclosures associated with IVDA and IVDAW.
Iveda Solutions, Inc., now a Delaware corporation listed on Nasdaq, reports continued operating losses while positioning itself as an AI-driven smart city and IoT platform provider. For the year ended December 31, 2025, it recorded a net loss of about $3.2 million, following a $4.0 million loss in 2024, and has accumulated losses of roughly $56 million.
The company depends heavily on its Taiwan subsidiary, which generated 85% of 2025 revenue and 87% of 2024 revenue, and on a small number of large customers; four customers made up 63% of 2025 revenue. Iveda offers AI video analytics (IvedaAI), IoT platforms (Cerebro), smart power solutions, smart poles, drones, health and elder-care devices, and industrial monitoring tools.
As of March 15, 2026, Iveda had 11,139,740 shares of common stock outstanding and significant U.S. net operating loss carryforwards of about $40.0 million federal and $11.0 million state. The company highlights risks from ongoing losses, reliance on key personnel, geopolitical uncertainty around Taiwan, cybersecurity gaps, and potential Nasdaq listing compliance issues.
Iveda Solutions, Inc. has been notified by Nasdaq that its common stock no longer meets the exchange’s minimum bid price requirement of $1 per share, after trading below that level for 30 consecutive business days. The notice does not immediately affect the stock’s Nasdaq listing.
The company has 180 calendar days, until September 2, 2026, to regain compliance. Nasdaq will deem the requirement met if the closing bid price is at least $1 for a minimum of ten consecutive business days during this period. If compliance is not restored or other listing rules are breached, Nasdaq may move to delist the shares, although Iveda could appeal any delisting determination to a Nasdaq Hearings Panel.
Iveda Solutions director Robert Gillen reported offsetting option transactions tied to an option repricing. He was granted 100,000 stock options on an "acquire" transaction and disposed of 100,000 options back to the issuer on a separate "disposition to issuer" transaction, leaving 128,599 options reported as held afterward.
According to a board-approved repricing on February 23, 2026, his options were reset to an exercise price of $0.29 per share while all other terms remained unchanged. The company states these transactions were exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.
Iveda Solutions Chief Financial Officer Robert J. Brilon reported changes to his stock options in a paired, non-cash transaction. He was granted 125,000 options and disposed of 125,000 options, both recorded as “Options (Right to Buy).” Following these transactions, he holds 152,503 derivative securities directly.
The company’s board approved an option repricing on February 23, 2026, resetting the exercise price of his options to $0.29 per share. The filing states that all other option terms remain unchanged and that the repricing was exempt under specific Exchange Act rules.
Iveda Solutions director Franco Alejandro reported an option repricing and related award. On February 23, 2026, the board approved a repricing of his options to an exercise price of $0.29 per share, with all other terms unchanged. This involved an acquisition of 25,000 options and a corresponding disposition of 25,000 options to the issuer, both recorded at a transaction price of $0.00 per option. Following these transactions, Alejandro directly held 53,130 options to acquire Iveda Solutions stock. The company notes these transactions were exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.
Iveda Solutions, Inc. reported that Chief Executive Officer David H. Ly had his stock options repriced by the board. On February 23, 2026, options covering 175,000 shares were granted or awarded, and a separate 175,000-option position was disposed of back to the issuer. According to the disclosure, the repricing set the exercise price at $0.29 per share, while all other option terms remained unchanged. After these offsetting derivative transactions, Ly directly held options to acquire 216,096 shares.
Iveda Solutions director Joseph A. Farnsworth reported option transactions tied to an option repricing. On February 23, 2026, he acquired 100,000 stock options at an exercise price of $0.29 per share and disposed of 100,000 options back to the company, with other option terms remaining unchanged.
Iveda Solutions reporting persons Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton disclose beneficial ownership of 1,158,920 shares, representing 9.99% of common stock as of 02/11/2026. The holdings consist of 857,143 shares of common stock and 1,714,286 warrants, but conversion of the warrants is contractually limited so the aggregate beneficial ownership has been capped at 1,158,920 shares.
The filing states that Lind Global Partners III LLC may be deemed to have sole voting and dispositive power for the partnership's shares and that Jeff Easton, as managing member, may be deemed to have sole voting and dispositive power. The filing includes a joint filing agreement and is signed on 02/19/2026.
Iveda Solutions, Inc. received a Schedule 13G reporting a significant but non-controlling position by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of the close of business on February 13, 2026, they may be deemed to beneficially own 592,195 shares of common stock issuable upon exercise of a warrant, representing about 4.99% of the outstanding common stock.
The filing explains that additional shares underlying several Intracoastal warrants are blocked from exercise if doing so would push ownership above limits of 4.99% or 9.99%. The reporting persons certify the securities were not acquired to change or influence control of Iveda.
Iveda Solutions, Inc. completed a public offering of 5,714,286 shares of common stock (or pre-funded warrants in lieu) and Series X warrants to purchase up to 11,428,572 shares at a combined price of $0.35. The transaction generated approximately $2 million in gross proceeds before fees and expenses. The company issued additional placement agent warrants and paid cash fees to H.C. Wainwright & Co. and plans to use the net proceeds for general corporate purposes, including potential R&D, debt repayment, working capital, capital spending, acquisitions, joint ventures, and stock repurchase programs. The offering was conducted under an effective Form S-1 registration statement.